The latest Business updates from the science industry
by Gwyneth Astles
Innovation Summit: Stay Ahead with New GC and GCMS Technology
We invite laboratory professionals in Asia Pacifi c and Japan region to experience the productivity evolution. Available on-demand, Thermo Fisher Scientifi c Innovation Summit: Stay Ahead with new GC and GCMS Technology will be benefi cial for users in environmental, pharmaceutical and food testing.
Session 1: The Reveal. The topics are: - Stay ahead with measurably more production - Stay ahead with unstoppable confi dence - New product demo
57429pr@reply-direct.com Session 2: Applied Technology. The topics are:
- The impact of smooth method transfers in a pharmaceutical Quality Control laboratory
- Uninterrupted analysis of volatile organic compounds in accordance with EPA and worldwide regulations
- Unstoppable analysis of pesticides residues in black tea using a new triple quadrupole GC-MS
Register for the on-demand session now. More information online:
ilmt.co/PL/yjJk
PEFTEC Returns LIVE to Rotterdam in June 2022
PEFTEC the conference and exhibition for Petrochemical and Oil analysis returns ‘LIVE’ on the 8th and 9th June 2022 at the Ahoy Exhibition centre in Rotterdam, The Netherlands. Following on from past successful Live and Virtual PEFTEC exhibitions the ‘LIVE’ 2022 event will give industry the opportunity to meet in person and face to face again. PEFTEC is a focused event dedicated to help, teach and advise analytical chemists, laboratory managers and process control and instrument users. Entry to the exhibition and conference is totally free to all attendees, reservations to the technical conference will be on a ‘fi rst come fi rst served’ allocation on the day.
PEFTEC organiser, Marcus Pattison, said: “PEFTEC is very much an industry lead event, we have a very strong scientifi c committee comprising of leading experts and end users from SABIC, Dow Chemical. Total, BASF, Borouge, The Research Institute of Chromatography, IFP Energies and leading academic contributors from the Universities of Rostock and KU Leuven.
“It’s been a while since Industry has been able to meet in person to discuss projects, new product developments and application solutions. PEFTEC attracts end users and instrument from around the global, the 2022 event will be a ‘Hybrid’ event which will allow delegates and visitors who are unable to travel to Rotterdam in person to join and interact with the event online.”
Over 100 leading instrument and technology suppliers will be exhibiting at PEFTEC to introduce, demonstrate and display new products and analytical solutions. To learn more, please visit the PEFTEC website.
More information online:
ilmt.co/PL/BpqR 57092pr@reply-direct.com
Collaboration Brings DFU and Inflammatory Disease Therapy to Greater China Region
regulatory submissions and commercialisation of the licensed products in the licensed territory with Shenzen-based Xbiome.
Shanghai-based Lynx Financial served as Aurealis’ exclusive
fi nancial advisor in this transaction, which will see the European company receive upfront payment, milestone payments and royalties on product sales, which could amount to in excess of $139 million going forward.
Juha Yrjänheikki Mr Yan Tan
Aurealis Therapeutics and AI-based microbiome drug development company Xbiome have entered into an agreement for the clinical development and commercialisation of Aurealis’ Diabetic Foot
investigational Ulcer (DFU) and other chronic wounds and
infl ammatory disease therapy in the Greater China territory. The agreement covers rights for all human use of the DFU drug candidate AUP-1 in Mainland China, Hong Kong, Macao and Taiwan and places responsibility for all clinical and other development,
Aurealis CEO Juha Yrjänheikki said: “We are extremely happy to partner with Xbiome. We are impressed of their expertise, agility in execution and commitment to the treatment of diabetes-related diseases and introducing AI microbiome-based treatment methods and drugs into the China market and beyond, of which AUP-16 will be a great example. We believe that this partnership will accelerate the development of AUP-16 as a potential new therapy for DFU and other chronic wound patients.”
“DFUs and other chronic wounds not only cause great pain, but also enormous costs to the society. We are very excited to collaborate with Xbiome and work together to develop a unique cure for these conditions with rapidly growing prevalence in China and globally. We are honoured to embark on this journey together with our colleagues at Xbiome,” continued Roger Meier, Aurealis Chairman of the Board.
Adding that the synthetic biology company’s cell and gene therapy technology made a perfect fi t with its microbiome-based drug development platform, Yan Tan, founder and CEO of Xbiome said: “Aurealis is one of the most innovative biotech companies we came across; most importantly we share the same vision and passion. We are extremely excited to collaborate with Aurealis to accelerate the development of AUP-16 in China and all over the world. It is just the beginning of a long-term partnership of two companies, we are thrilled to embark on this journey and explore more possibilities in the future.”
Donald Xu, Managing Partner of Lynx Financial added: “We are witnessing here two young and rising companies join forces to develop a fi rst- and best-in-class therapy for these debilitating chronic wound indications. This synergistic collaboration between a Chinese and a European company truly underscores the global trend in innovation and development within the pharmaceutical and biotech industries.”
More information online:
ilmt.co/PL/xr0k 57131pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52
